A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization

Trial Profile

A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms GLAGOV; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 29 Aug 2017 Detailed results from this trial were presented in a Late-Breaking Clinical Trials session at the European Society of Cardiology (ESC) Congress 2017, as reported in an Amgen Media Release
    • 29 Aug 2017 Results of an exploratory virtual histology sub-study (n=331) published in an Amgen Media Release
    • 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top